Skip to main content
. 2023 Dec 8;200(5):400–408. doi: 10.1007/s00066-023-02180-9

Fig. 1.

Fig. 1

Kaplan–Meier curves presenting a overall survival (OS) of patients with oligometastatic disease (OMD) who received stereotactic radiotherapy, b progression-free survival (PFS) of the entire cohort, c local control (LC) rate of treated lesions, d time to introduction of systemic treatment, systemic treatment-free survival (STFS), for de novo OMD patients. grey curves present the 95% confidence interval